改善全球结果(KDIGO)慢性肾脏病糖尿病管理的临床实践指南代表了关于该主题的第一个KDIGO指南。该指南出台之际,糖尿病技术和治疗方法的进步提供了新的选择,以管理健康状况不佳的高风险的大量糖尿病和慢性肾脏疾病(CKD)患者。越来越多的来自随机临床试验的高质量证据可用于评估提供器官保护的重要新疗法,例如钠-葡萄糖协同转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂。新指南的目标是通过将新选择与现有管理策略相结合,提供循证建议,以优化糖尿病和CKD患者的临床护理。此外,该指南包含实践要点,以便在没有足够数据来提出合理建议时,或在其他指导可能对临床应用有用时,便于实施.该指南涵盖糖尿病和CKD患者的全面护理,血糖监测和目标,生活方式干预,抗高血糖疗法,以及自我管理和卫生系统方法来管理糖尿病和CKD患者。
Improving Global Outcomes (KDIGO) Clinical Practice
Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO
guideline on this subject. The
guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new
guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the
guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.